Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gene Friend Way Inc. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner and a distinct art unit. The concentration of the current workload indicates a focused prosecution effort on a single matter. This allows the company to direct its intellectual property resources toward a specific goal within the Biotechnology & Pharmaceuticals sector. By working with a single examiner, the applicant can establish a clear line of communication and better understand the examiner's specific concerns.
FONSECA LOPEZ, FRANCINI ALVARENGA is the busiest examiner, with 1 pending office action. This examiner oversees the only active office action for the company. Consequently, the success of the current prosecution cycle depends on the interaction with this specific examiner and the standards of the single art unit involved. Because there is 1 pending office action, the applicant can provide a very detailed and targeted response. The presence of 1 pending office action with FONSECA LOPEZ, FRANCINI ALVARENGA ensures that the company's attention is not divided across multiple pending matters. This streamlined profile is conducive to a thorough and focused prosecution process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FONSECA LOPEZ, FRANCINI ALVARENGA | 1 | 29.6% | +37.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17849653 | MACHINE LEARNING MODELS FOR DETERMINING PATHOGENIC GENETIC VARIANTS | FONSECA LOPEZ, FRANCINI ALVARENGA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17849653 | MACHINE LEARNING MODELS FOR DETERMINING PATHOGENIC GENETIC VARIANTS | FONSECA LOPEZ, FRANCINI ALVARENGA | — |
| Art Unit | Apps |
|---|---|
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17849653 | MACHINE LEARNING MODELS FOR DETERMINING PATHOGENIC GENETIC VARIANTS | FONSECA LOPEZ, FRANCINI ALVARENGA | 1685 | §101§103 | Final Rejection | — | Pending | Jun 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGene Friend Way Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Francini Alvarenga Fonseca Lopez has the most, with 1 of Gene Friend Way Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.